Increased renal tubular expression of transforming growth factor beta in human allografts correlates with cyclosporine toxicity

Kidney International

Volumn 50, Issue 5, 1996, Pages 1634-1640

  Pankewycz, Oleh G ^a,b   Miao, Li ^a   Isaacs, Ross ^a   Guan, Jing ^a   Pruett, Tim ^a   Haussmann, Gail ^a   Sturgill, B C ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0029906111     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.479     Document Type: Article

References (40)

1. CALNE RY: Cyclosporin in cadaveric renal transplantation: 5-year follow up of a multicenter trial. Lancet 2:506-507, 1987
2. STILLER CR, OPELZ G: Should cyclosporin be continued indefinitely? Transplant Proc 23:36-40, 1991
3. BURKE JF, PIRSCH JD, RAMOS EL, SALOMON DR, STABLEIN DM, VAN BUREN DH, WEST JC: Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 331:358-363, 1994
4. MYER BD: Cyclosporine nephrotoxicity. Kidney Int 30:964-974, 1986
5. STEINMULLER DR: Cyclosporine nephrotoxicity. Cleveland Clinic J Med 56:89-95, 1989
6. KAHAN BD: Cyclosporine. N Engl J Med 321:1725-1738, 1989
7. DIEPERINK H, LEYSSAC PP, KEMP E, STARKLINT H, FRANDSEN NE, TVEDE N, MOLLER J, BUCHLER-FREDERIKSEN P, ROSSING N: Nephrotoxicity of cyclosporin A in humans: Effects on glomerular filtration and tubular reabsorption rates. Eur J Clin Invest 17:493-496, 1987
8. KLINTMALM EB, IWATSUKI S, STARZL TE: Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1:470-471, 1981
9. NAJARIAN JS, FRYD DS, STRAND M, CANAFAX DM, ASCHER NL, PAYNE WD, SIMMONS RL, SUTHERLAND DE: A single institution, randomized prospective trail of cyclosporin vs. azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg 201:142-157, 1985
10. NOVICK AC, HWEI HH, STEINMULLER D, STREEM SB, CUNNINGHAM RJ, STEINHILBER D, GOORMASTIC M, BUSZT A: Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study. Transplantation 42:152-158, 1986
11. ABOUNA CM, SAMHAN MS, KUMAR MSA, WHITE AC, SILVA OSG: Limiting factors in successful preservation of cadaveric kidneys with ischemic time exceeding 50 hours. Transplant Proc 19:2051-2055, 1987
12. FERGUSON RM, SOMMER BG: Cyclosporine in renal transplantation: A single institutional experience. Am J Kidney Dis 5:296-306, 1985
13. KLINTMALM G, BOHMAN SO, SUNDELIN B, WILCAEK H: Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: Beneficial effect of low doses in early post-transplantation period. Lancet 2:950-954, 1984
14. PALESTINE AG, AUSTIN HA, BALOW JE, ANTONOVYCH TT, SABNIS SG, PREUSS HG, NUSSENBLATT RB: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 20:1293-1298, 1986
15. MYERS BD, ROSS J, NEWTON L, LUETSCHER J, PERLROTH M: Cyclosporine-associated chronic nephropathy. N Engl J Med 311:699-705, 1984
16. MIHATSCH MJ, THIEL G, BASLER V, RYFFEL B, LANDMANN J, VON OVERBECK J, ZOLLINGER HU: Morphological patterns in cyclosporin treated renal transplant recipients. Transplant Proc 17(Suppl 1):101-116, 1985
17. PALESTINE AG, NUSSENBLATT RB, CHAN C-C: Side effects of systemic cyclosporin in patients not undergoing transplantation. Am J Med 77:652-656, 1984
18. MYERS BD, SIBLEY R, NEWTON L, TOMLANOVICH SJ, BOSHKOS C, STINSEON E, LUETSCHER JA, WHITNEY DJ, KRANSNY D, COPLON NS, PERLROTH MG: The long-term course of cyclosporine associated chronic nephropathy. Kidney Int 33:590-600, 1988
19. THIEL G, FELLMANN T, ROSMAN J, BOCK A, LANDMANN J, MIHATSCH M: Long-term safety profile of Sandimmune in renal transplantation. Transplant Proc 24(Suppl 2):71-77, 1992
20. MIHATSCH MJ: Selectivity still has its price: Personal experiences with cyclosporine over the last 10 years. Transplant Proc 24(Suppl 2):67-70, 1992
21. FIRST MR: Renal allograft survival after 1 and 10 years: Comparison between pre-cyclosporin and cyclosporin data. Nephrol Dial Transplant 9:90-97, 1993
22. FIRST MR: Ten years of cyclosporin A. Transplantation 10:1-24, 1994
23. KAHAN BD, GREVEL J: Optimization of cyclosporin therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 20(Suppl 2):575-584, 1988
24. UBHI CS, WOODHOUSE L, GUILLOU PJ, GILES GR: Is there a therapeutic range for monitoring plasma cyclosporin in renal allograft recipients? Nephrol Dial Transplant 3:814-819, 1988
25. WOLF G, THAISS F, STAHL RA: Cyclosporin stimulates expression of transforming growth factor-β in renal cells. Transplantation 60:237-241, 1995
26. AHUJA SS, SHRIVASTAV S, DANIELPOUR D, BALOW JE, BOUMPAS DT: Regulation of transforming growth factor-β1 and its receptor by cyclosporin in human T lymphocytes. Transplantation 60:718-723, 1995
27. SHIHAB FS, YAMAMOTO T, NAST CC, COHEN AH, NOBLE NA, GOLD LI, BORDER WA: Transforming growth factor-β and matrix protein expression in acute and chronic rejection in human renal allografts. J Am Soc Nephrol 6:286-294, 1995
28. PRASHAR Y, KHANNA A, SEHAJPAL P, SHARMA VK, SUTHANTHIRAN M: Stimulation of transforming growth factor-β1 transcription by cyclosporin. FEBS Lett 358:109-112, 1995
29. SHEHATA M, COPE GH, JOHNSON TS, RAFTERY AT, EL NAHAS AM: Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Int 48:1487-1496, 1995
30. COUPES BM, NEWSTEAD CG, SHORT CD, BRENCHLEY PE: Transforming growth factor β1 in renal allograft recipients. Transplantation 57:1727-1731, 1994
31. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, BURDICK JF, COHEN AH, COLVIN RB, CROKER BP, DROZ D, DUNNILL MS, HALLORAN PF, HAYRY P, JENNETTE JC, KEOWN PA, MARCUSSEN N, MIHATSCH MJ, MORZUMI K, MYERS BD, NAST CC, OLSEN S, RACUSEN LC, RAMOS EL, ROSEN S, SACHS DH, SALOMON DR, SANFILIPPO F, VERAMI R, VON WILLEBRAND E, YAMAGUCKI Y: International standardization of criteria for the histologic dignosis of kidney transplant pathology. Kidney Int 44:411-422, 1993
32. DASCH JR, PACE DR, WAEGELL W, INENAGA D, ELLINGSWORTH L: Monoclonal antibodies recognizing transforming growth factor-β. J Immunol 142:1536-1541, 1989
33. PICHLER RH, FRANCESCHINI N, YOUNG BA, HUGO C, ANDOH TF, BURDMANN EA, SHANKLAND SJ, ALPERS CE, BENNETT WM, COUSER WG, JOHNSON RJ: Pathogenesis of cyclosporin nephrotoxicity: Roles of angiotensin II and osteopontin. J Am Soc Nephrol 6:1186-1196, 1995
34. SHARMA K, ZIYADEH FN: Renal hypertrophy is associated with upregulation of TGF-β1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 267:F1094-F1101, 1994
35. SULLIVAN BA, HAK LJ, FUNN WF: Cyclosporin nephrotoxicity: Studies in laboratory animals. Transplant Proc 17(Suppl 1):145-154, 1985
36. WANG JC, XU G, LI B, MOURADIAN J, CHEIGH JS, RIGGIO RR, STENZL KH, SUTHANTHIRAN M: Human renal graft rejection: Molecular characterization including quantification of intragraft gene expression. (abstract) J Am Soc Nephrol 3:849, 1992
37. NORONHA H, HARLEY B, CAMERON JS, WALDHERR R: Evaluation of cytokines, growth factors and their receptors in situ in renal allograft biopsies. (abstract) J Am Soc Nephrol 3:873, 1993
38. WAHL SM: Transforming growth factor beta: The good, bad and the ugly. J Exp Med 180:1587-1590, 1994
39. BORDER WA, NOBLE NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
40. FEUTREN G, MIHATSH MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326:1654-1660, 1992